NASDAQ:OPGN - OpGen Stock Price, Forecast & News

OpGen trades on the NASDAQ under the ticker symbol "OPGN."

Shares of OpGen reverse split on the morning of Friday, January 19th 2018. The 1-25 reverse split was announced on Wednesday, January 17th 2018. The number of shares owned by shareholders was adjusted after the market closes on Thursday, January 18th 2018. An investor that had 100 shares of OpGen stock prior to the reverse split would have 4 shares after the split.

OpGen Inc (NASDAQ:OPGN) released its earnings results on Wednesday, November, 6th. The medical research company reported ($3.34) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.60) by $0.74. The medical research company earned $0.65 million during the quarter, compared to the consensus estimate of $0.90 million. OpGen had a negative net margin of 397.44% and a negative return on equity of 662.90%. View OpGen's Earnings History.

OpGen is scheduled to release their next quarterly earnings announcement on Tuesday, February 25th 2020. View Earnings Estimates for OpGen.

OpGen issued an update on its FY 2019 After-Hours earnings guidance on Wednesday, February, 12th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $3.5-3.5 million, compared to the consensus revenue estimate of $3.55 million.

3 analysts have issued 1 year price objectives for OpGen's stock. Their forecasts range from $1.50 to $20.00. On average, they expect OpGen's share price to reach $7.93 in the next twelve months. This suggests a possible upside of 386.7% from the stock's current price. View Analyst Price Targets for OpGen.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for OpGen in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for OpGen.

Media coverage about OPGN stock has been trending somewhat positive this week, InfoTrie reports. The research firm identifies negative and positive news coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. OpGen earned a media sentiment score of 1.8 on InfoTrie's scale. They also assigned media coverage about the medical research company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the company's share price in the near term. View News Stories for OpGen.

OpGen saw a decline in short interest in January. As of January 31st, there was short interest totalling 80,900 shares, a decline of 61.7% from the January 15th total of 211,200 shares. Based on an average daily trading volume, of 865,400 shares, the days-to-cover ratio is presently 0.1 days. Currently, 1.5% of the shares of the company are short sold. View OpGen's Current Options Chain.

Some companies that are related to OpGen include Miragen Therapeutics (MGEN), PotNetwork (POTN), Biocept (BIOC), Avant Diagnostics (AVDX), CBA Florida (CBAI), Cancer Genetics (CGIX), First Choice Healthcare Solutions (FCHS) and Aeon Global Health (AGHC).

Based on aggregate information from My MarketBeat watchlists, some companies that other OpGen investors own include Anavex Life Sciences (AVXL), Agile Therapeutics (AGRX), Inovio Pharmaceuticals (INO), vTv Therapeutics (VTVT), Energy Transfer LP Unit (ET), Nabriva Therapeutics (NBRV), Vaxart (VXRT), Protalix Biotherapeutics (PLX), TrovaGene (TROV) and Melinta Therapeutics (MLNT).

(OPGN) raised $17 million in an IPO on Tuesday, May 5th 2015. The company issued 2,900,000 shares at a price of $5.50-$6.50 per share. Maxim Group acted as the underwriter for the IPO and National Securities was co-manager.

OpGen's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Renaissance Technologies LLC (1.22%), Virtu Financial LLC (0.96%) and Oxford Asset Management LLP (0.41%). View Institutional Ownership Trends for OpGen.

OPGN stock was bought by a variety of institutional investors in the last quarter, including Virtu Financial LLC, Renaissance Technologies LLC and Oxford Asset Management LLP. View Insider Buying and Selling for OpGen.

Shares of OPGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of OPGN stock can currently be purchased for approximately $1.63.

OpGen has a market capitalization of $9.13 million and generates $2.95 million in revenue each year. The medical research company earns $-13,370,000.00 in net income (profit) each year or ($44.40) on an earnings per share basis. OpGen employs 44 workers across the globe.View Additional Information About OpGen.

The official website for OpGen is http://www.opgen.com/.

OpGen's mailing address is 708 QUINCE ORCHARD ROAD SUITE 205, GAITHERSBURG MD, 20878. The medical research company can be reached via phone at 240-813-1260 or via email at [email protected]